New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100® Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting
11 Ottobre 2023 - 2:00PM
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume
measurement technology, today announces new data from Banner
University Medicine Advanced Heart Failure Clinic in Phoenix, AZ
validating the benefits of the Company’s BVA-100 diagnostic blood
test for ambulatory patients with advanced heart failure. Data were
presented at the Annual Scientific Meeting of the Heart Failure
Society of America (HFSA), which brought together the world’s
leading experts in heart failure at the Huntington Convention
Center in Cleveland, OH on October 8, 2023.
Key findings included:
- The urgent need for
BVA to guide care was shown by the discordance between clinician
estimates of total and red blood cell volumes and measured volumes
was present in 48% of the patients for total blood volume and in
64% of patients for red blood cell volume in the initial
twenty-five patients
- Most patients had
severe blood volume derangements as measured with BVA, only 41% of
patients had normal total blood volume, and only 29% had normal red
blood cell volume
- BVA optimized care
and led to better outcomes In the study’s outpatient advanced heart
failure clinic, incorporating BVA allowed diagnosis of common,
often severe, and clinically unsuspected variances in total blood
and red blood cell volumes
The study titled, “The Value of Blood Volume
Analysis to Guide Ambulatory Advanced Heart Failure Care,” measured
individual blood volumes in eighty-three ambulatory patients with
advanced heart failure utilizing BVA to determine the benefits of
quantitative blood volume measurements not otherwise obtainable
using traditional methods such as clinical signs, symptoms, and
exam. “The frequency of the variances in red blood cell volume
tended to be greater and more severe than those found in total
blood volume. Identifying variances in red blood cell volumes
provides an opportunity to evaluate and treat these patients, and
our patients in general have benefitted from treatment of both
total blood and red blood cell volume,” said Marc A. Silver, MD,
FACP, FACC, FCCP, FAHA, FHFSA, principal investigator, and Faculty,
Advanced Heart Failure Cardiologist at Banner University Medical
Center.
Michael Feldschuh, Daxor’s CEO and President
said, “Management of diuretic strategies remains one of the most
difficult and challenging problems clinicians encounter in heart
failure patients. This study provides further evidence that our BVA
technology is a practical and effective solution to the challenge
of optimizing heart failure care in both the inpatient and
outpatient settings, and use of our diagnostic confirms that
surrogate markers such a physical exam are not accurate or precise
compared to direct and objective measurement with Daxor’s BVA
system.”
About Daxor Corporation
Daxor Corporation (NASDAQ: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the only diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. Over 65,000+ tests have been performed at leading hospital
centers across the U.S., enhancing hospital performance metrics in
a broad range of surgical and medical conditions, including
significantly reducing mortality and readmissions in heart failure
and critical care. Daxor has several ongoing trials in the areas of
heart failure treatment with support from the NIH and is under
contract developing analyzers to improve combat casualty care with
the U.S. Department of Defense. Daxor's mission is to advance
healthcare by enabling optimal fluid management with blood volume
analysis. Daxor’s vision is optimal blood volume for all. For more
information, please visit our website at Daxor.com. Sign up to
receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr.
Managing Partner, CORE IR1-516-222-2560brets@coreir.com
Grafico Azioni Daxor (NASDAQ:DXR)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Daxor (NASDAQ:DXR)
Storico
Da Set 2023 a Set 2024